•Collected By National Basic Medical Insurance Category B

•National-level Key New Product

•The only innovative TCM that the Evidence-based medicine research has confirmed its treatment for chronic heart failure

•The only innovative TCM cited by the guidelines of diagnosis and treatment of heart failure of Chinese Medical Association

Qili Qiangxin capsule not only has the traditional functions in cardiac, diuretic, vasodilators to improve hemodynamic disorders, significantly improve the symptoms of chronic heart failure (treating symptoms); more importantly, also be able to intervene with neuroendocrine over-activation, reduce ventricular remodeling and thus improve the biological characteristics of heart (treating root cause). It shows the advantage of compound traditional Chinese medicine in multi-link, multi-path and multi-direction treatment.

【Ingredients】

Astragali Radix, Ginseng Radix et Rhizoma, Aconiti Lateralis Radix Preparata, Salvia miltiorrhiza Radix et Rhizoma, Descurainiae Semen lepidii Semen, Alismatis Rhizoma, Polygonati Odorati Rhizoma, Cinnamomi Ramulus, Carthami Flos, Periplocae Cortex, Citri Reticulatae Pericarpium.

【Indications】

To tonify qi, warm yang, activate blood, unblock the collaterals, promote urination and alleviate edema. Mild and moderate congestive heart failure of yang qi deficiency, obstruction of collaterals and water retention manifested as palpitations and shortness of breath worsening upon physical movement, difficulty in lying down, edema in the lower limbs, fatigue, lack of strength, scanty urine, cyanotic mouth and lips, fear of cold with cold limbs, and expectoration of thin white sputum; Coronary heart disease and hypertension with the symptoms described above.

【Clinical Application】

• Significantly reduce NT-pro BNP level, reduce re-hospitalization rate, reduce the rate of composite end points and improve prognosis.

• Significantly increase left ventricular ejection fraction, increase 6 minutes walking distance, reduce the score of Minnesota Living With Heart Failure (MLHF), improve symptoms of heart failure patients in dyspnea, fatigue, oliguria, edema, etc.

• Significantly reduce angiotensin Ⅱ level, intervene with neuroendocrine over-activation, delay the further development of ventricular remodeling.

• Significant increase in myocardial contractility.

• Significant diuretic efficacy.

【Dosage】Take orally, 4 capsules/time, 3 times/day.

【Specification】0.3g/capsule.

【Packing】Blister package, 36 capsules/box, 400boxes/carton.

【MA Number】License of State Drug Administration Z20040141.